NEW PRODUCT DEVELOPMENT

NEW PRODUCT DEVELOPMENT & COMMERCIALIZATION

Over 25 years experience with biotechnology new product development impacting health globally including initiatives listed below.
Over 25 years experience with biotechnology new product development impacting health globally including initiatives listed below.

DIAGNOSTICS & GLOBAL PUBLIC HEALTH
  • Developed groundbreaking FDA-cleared diagnostics and FDA-approved screening tests including current molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus) (Gen-Probe) (see list)
  • Launched first FDA-cleared combined chlamydia and gonorrhea molecular tests, eliminated need for male genital swabbing with first molecular testing for urine (Gen-Probe)
  • Supported protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings (St. Gabriel’s Hospital Malawi)
  • Developed prototype oncology biomarker detection platform (Intrexon)

ENVIRONMENTAL HEALTH & BIOSECURITY

  • Developed novel molecular diagnostics and environmental biothreat detection systems for US Intelligence Community (Vectrant)
  • Advanced multiple technologies for vector control and to mitigate mosquito-borne infectious disease transmission (developed West Nile Virus blood bank screening test, advanced genetically engineered mosquitoes, volunteered global health fieldwork to distribute mosquito nets and provide vector control and malaria health education) (Gen-Probe, Intrexon, Oxitec, St. Gabriel’s Hospital Malawi)
  • Deep expertise with genetically engineered, gene-edited, and cloned organisms serving as first-in-class for EPA and USFWS regulators (Intrexon)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (i.e., 1,4-dioxane) (Intrexon)
  • Advanced genetically engineered invasive species control technologies (Intrexon, Oxitec)
  • Engaged federal, state, and local governments to advance mosquito-borne infectious disease vector control interventions aimed at dengue and Zika, and helped gain support of Gates Foundation for pilot program addressing malaria (Intrexon, Oxitec)
DIAGNOSTICS & GLOBAL PUBLIC HEALTH
  • Developed groundbreaking FDA-cleared diagnostics and FDA-approved screening tests including current molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus) (Gen-Probe) (see list)
  • Launched first FDA-cleared combined chlamydia and gonorrhea molecular tests, eliminated need for male genital swabbing with first molecular testing for urine (Gen-Probe)
  • Supported protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings (St. Gabriel’s Hospital Malawi)
  • Developed prototype oncology biomarker detection platform (Intrexon)

ENVIRONMENTAL HEALTH & BIOSECURITY

  • Developed novel molecular diagnostics and environmental biothreat detection systems for US Intelligence Community (Vectrant)
  • Advanced multiple technologies for vector control and to mitigate mosquito-borne infectious disease transmission (developed West Nile Virus blood bank screening test, advanced genetically engineered mosquitoes, volunteered global health fieldwork to distribute mosquito nets and provide vector control and malaria health education) (Gen-Probe, Intrexon, Oxitec, St. Gabriel’s Hospital Malawi)
  • Deep expertise with genetically engineered, gene-edited, and cloned organisms serving as first-in-class for EPA and USFWS regulators (Intrexon)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (i.e., 1,4-dioxane) (Intrexon)
  • Advanced genetically engineered invasive species control technologies (Intrexon, Oxitec)
  • Engaged federal, state, and local governments to advance mosquito-borne infectious disease vector control interventions aimed at dengue and Zika, and helped gain support of Gates Foundation for pilot program addressing malaria (Intrexon, Oxitec)
Return to MY WORK | MISSION
Return to MY WORK | MISSION